Abstract:Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases worldwide with an unclear mechanism. Long non-coding RNAs (lncRNAs) have recently emerged as important regulatory molecules. To better understand NAFLD pathogenesis, lncRNA and messenger RNA (mRNA) microarrays were conducted in an NAFLD rodent model. Potential target genes of significantly changed lncRNA were predicted using cis/trans-regulatory algorithms. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were then performed to explore their function. In the current analysis, 89 upregulated and 177 downregulated mRNAs were identified, together with 291 deregulated lncRNAs. Bioinformatic analysis of these RNAs has categorized these RNAs into pathways including arachidonic acid metabolism, circadian rhythm, linoleic acid metabolism, peroxisome proliferator-activated receptor (PPAR) signaling pathway, sphingolipid metabolism, steroid biosynthesis, tryptophan metabolism and tyrosine metabolism were compromised. Quantitative polymerase chain reaction (qPCR) of representative nine mRNAs and eight lncRNAs (named fatty liver-related lncRNA, FLRL) was conducted and this verified previous microarray results. Several lncRNAs, such as FLRL1, FLRL6 and FLRL2 demonstrated to be involved in circadian rhythm targeting period circadian clock 3 (Per3), Per2 and aryl hydrocarbon receptor nuclear translocator-like (Arntl), respectively. While FLRL8, FLRL3 and FLRL7 showed a potential role in PPAR signaling pathway through interaction with fatty acid binding protein 5 (Fabp5), lipoprotein lipase (Lpl) and fatty acid desaturase 2 (Fads2). Functional experiments showed that interfering of lncRNA FLRL2 expression affected the expression of predicted target, circadian rhythm gene Arntl. Moreover, both FLRL2 and Arntl were downregulated in the NAFLD cellular model. The current study identified lncRNA and corresponding mRNA in NAFLD, providing new insight into the pathogenesis of NAFLD. Moreover, we identified a new lncRNA FLRL2, that might participate NAFLD pathogenesis mediated by Arntl.

Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: A study of human and animals

Combined with multiplex and network analysis to reveal the key genes and mechanisms of nonalcoholic fatty liver disease

Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease

Long Non-Coding Rna Profiling In A Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight Into Pathogenesis

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Target genes associated with lipid and glucose metabolism in non-alcoholic fatty liver disease

Identification of Key Pathways and Genes in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis

Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease.

Identification of gene expression patterns in rat model of nonalcoholic fatty liver disease

Identification of key target genes and pathway analysis in nonalcoholic fatty liver disease via integrated bioinformatics analysis

A Comprehensive Bioinformatics Analysis on Multiple Gene Expression Omnibus Datasets of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis

Identification of disease-related genes and construction of a gene co-expression database in non-alcoholic fatty liver disease

Hepatic Transcriptome Signatures in Mice and Humans with Nonalcoholic Fatty Liver Disease

Integrated transcriptomic landscape of the effect of anti‐steatotic treatments in high‐fat diet mouse models of non‐alcoholic fatty liver disease

Multi-omics analysis of the biological mechanism of the pathogenesis of non-alcoholic fatty liver disease

Identification of Key Genes and Pathways in Mild and Severe Nonalcoholic Fatty Liver Disease by Integrative Analysis.

The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice

Integrating Multi-Omics Reveals Crucial Biomarkers in Non-Alcoholic Fatty Liver Disease

Comparison of Hepatic Gene Expression Profiles Between Three Mouse Models of Nonalcoholic Fatty Liver Disease

Identification of novel targets associated with cholesterol metabolism in nonalcoholic fatty liver disease: a comprehensive study using Mendelian randomization combined with transcriptome analysis